Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Hu Z, Li X, Yuan R, Ring BZ, Su L (2010) Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 120:705–714CrossRefPubMed
2.
Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112PubMed
3.
Zhuo W, Zhang Y, Xiang Z, Cai L, Chen Z (2009) Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res 28:115CrossRefPubMedPubMedCentral
Metadata
Title
A small number of subjects do not always indicate that they are minor variants data for inclusion in a pooled analysis
Authors
Pei-Hua Lu
Min-Bin Chen
Mu-Xin Wei
Zhi-Yang Jiang
Chen Li
Publication date
01-02-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1234-z

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue

Epidemiology

Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study

Epidemiology

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

Letter to the Editor

Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: appraisal of a recent meta-analysis

Epidemiology

Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics

Brief Report

Reversed urban–rural differences in breast cancer mortality (China, 2002–2008)

Letter to the Editor

Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits